About US
Contact us
-
Merck acquires Swiss oncology drug development company OncoEthixUS-based drugmaker Merck has acquired Swiss biotechnology company specialised in oncology drug development, OncoEthix. Merck acquired the company through a subsidiary. OncoEthix will receive an upfr2014/12/24
-
AstraZeneca’s Lynparza obtains European approval for BRCA-mutated ovarian cancerBritish-Swedish drugmaker AstraZeneca has obtained approval from the European Commission (EC) for its twice-daily Lynparza (olaparib) capsules (400mg). Lynparza capsules can be first therapy to treat2014/12/23
-
Lilly, Adocia team up to develop BioChaperone Lispro insulin for treatment of diabetesEli Lilly and Company (NYSE: LLY) and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChapero2014/12/23
-
FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infectionThe U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV) VIEKIRA PAK™, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patient2014/12/22
-
NICE recommends Boehringer Ingelheim's Pradaxa to treat fatal blood clots in adultsThe UK's National Institute for Health and Care Excellence (NICE) has recommended the anti-blood clotting drug dabigatran, Boehringer Ingelheim's Pradaxa, to treat fatal blood clots in the legs (deep2014/12/22
-
Pharma Technology Focus - Issue 33The rate of M&A activity in the pharma industry is showing no signs of slowing down, but will the resulting lack of healthy competition lead to a decline in research and innovation? We investigate2014/12/22
-
GSK forms new European consortium to advance Ebola vaccine candidateGlaxoSmithKline (GSK) and three leading research institutions have formed a new European consortium to help further advance development of a candidate vaccine against Ebola. The Ebola vaccine candida2014/12/19
-
Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157Chimerix, Inc. (NASDAQ: CMRX) a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical2014/12/19
-
High-dose flu vaccine better than regular flu shot for frail, older adults of long-term care facilitiesThe high-dose flu vaccine is significantly better than the regular flu shot at boosting the immune response to the flu virus in frail, older residents of long-term care facilities, according to the re2014/12/18
-
Pfizer and OPKO collaborate to develop and commercialise hGH-CTP to treat GHDUS-based drug maker Pfizer has signed a worldwide agreement with OPKO Health to develop and commercialise hGH-CTP to treat growth hormone deficiency (GHD) in adults and children. The agreement includ2014/12/18